SecBot SecBot
SECBOTREPLAY Home › Report › OLMA

OLMA · Olema Oncology announced preliminary Phase 1 data for OP-3136, a KAT6…

Olema Oncology · PRESS-RELEASE filed May 21, 2026 at 17:00 ET

At the news

BULLISHIMPACT 6/10

PRESS-RELEASE filed May 21, 2026 at 17:00 ET

Olema Oncology announced preliminary Phase 1 data for OP-3136, a KAT6 inhibitor, showing acceptable tolerability and early anti-tumor activity across solid tumors. The data will be presented at ASCO 2026. While the safety profile and tumor shrinkage in 13 of 19 evaluable patients are encouraging, the sample is small and heavily pretreated, limiting immediate commercial read-through.

  • OP-3136 monotherapy showed no dose-limiting toxicities and no discontinuations due to TRAEs across doses up to 45 mg/day.
  • Among 19 response-evaluable patients, tumor shrinkage was observed in 13 patients; 2 confirmed PRs and 1 unconfirmed PR.
  • Most common TRAEs were dysgeusia (81% any grade), anemia (38% any grade; 6% grade 3), and neutropenia (34% any grade; 28% grade 3).
  • 11 of 32 patients remain on treatment; longest treatment duration is 62 weeks.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access